S(+)-Ibuprofen Effects on Asprin Treated Volunteers

Gebro Pharma GmbH72 enrolled

Overview

The purpose of this clinical trial is to determine whether S(+)-ibuprofen affect the platelet inhibition under steady state acetylsalicylic acid conditions.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Drug Interactions

Interventions

S(+)-ibuprofenDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy caucasian volunteer * Must be able to swallow tablets Exclusion Criteria: * Underlying diseases * Ulcus pepticum in history * Abuse of alcoholic beverages (40g/d) * Hypersensitivity to investigational medicinal products

Locations (1)

Department of Clinical Pharmacology, Medical University Vienna

Vienna, State of Vienna, Austria

Outcomes

Primary Outcomes

Percentage of inhibition of TxB2 after 1, 3, 7 and 10 days

Secondary Outcomes

percentage of subjects with >90% inhibition of TxB2, CEPI-CT and CADP-CT measured by PAF100,

prostacyclin metabolite

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.